A5064618296- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Treatment and Research
- Urinary and Genital Oncology Studies
- Renal cell carcinoma treatment
- Epigenetics and DNA Methylation
- Prostate Cancer Diagnosis and Treatment
- Renal and related cancers
- Urological Disorders and Treatments
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Urologic and reproductive health conditions
- Cancer, Lipids, and Metabolism
- Genital Health and Disease
- Immunotherapy and Immune Responses
- Molecular Biology Techniques and Applications
- Ferroptosis and cancer prognosis
- Cancer, Hypoxia, and Metabolism
- Immune Cell Function and Interaction
- Cancer-related molecular mechanisms research
- Peptidase Inhibition and Analysis
- Cancer Research and Treatments
- Metastasis and carcinoma case studies
- RNA modifications and cancer
- Cancer Diagnosis and Treatment
- Gut microbiota and health
University of Pennsylvania
2023-2025
University of Alabama at Birmingham
2017-2024
Johns Hopkins University
2013-2023
Sidney Kimmel Comprehensive Cancer Center
2008-2023
Texas Oncology
2007-2023
University of Colorado Denver
2010-2023
University of Colorado Cancer Center
2010-2023
O'Neal Comprehensive Cancer Center
2022-2023
Johns Hopkins Hospital
2010-2022
University of Michigan
2009-2022
The development of noninvasive methods to detect and monitor tumors continues be a major challenge in oncology. We used digital polymerase chain reaction-based technologies evaluate the ability circulating tumor DNA (ctDNA) 640 patients with various cancer types. found that ctDNA was detectable >75% advanced pancreatic, ovarian, colorectal, bladder, gastroesophageal, breast, melanoma, hepatocellular, head neck cancers, but less than 50% primary brain, renal, prostate, or thyroid cancers. In...
Inhibitory receptors on immune cells are pivotal regulators of escape in cancer. Among these inhibitory receptors, CTLA-4 (targeted clinically by ipilimumab) serves as a dominant off-switch while other such PD-1 and LAG-3 seem to serve more subtle rheostat functions. However, the extent synergy cooperative interactions between pathways cancer remain largely unexplored. Here, we reveal extensive coexpression tumor-infiltrating CD4(+) CD8(+) T three distinct transplantable tumors. Dual...
Cancer genomic, transcriptomic, and proteomic profiling has generated extensive data that necessitate the development of tools for its analysis dissemination. We developed UALCAN to provide a portal easy exploring, analyzing, visualizing these data, allowing users integrate better understand gene, proteins, pathways perturbed in cancer make discoveries. web enables analyzing delivering transcriptome, proteomics, patient survival research community. With obtained from The Genome Atlas (TCGA)...
The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options localized disease, management of recurrent advanced disease clinicians who treat patients with prostate cancer. portions the guidelines included herein focus on roles germline somatic genetic testing, nomograms tumor multigene molecular androgen deprivation therapy, secondary hormonal chemotherapy, immunotherapy in
Malignant cells, like all actively growing must maintain their telomeres, but genetic mechanisms responsible for telomere maintenance in tumors have only recently been discovered. In particular, mutations of the binding proteins alpha thalassemia/mental retardation syndrome X-linked ( ATRX ) or death-domain associated protein DAXX shown to underlie a mechanism not involving telomerase (alternative lengthening telomeres), and point promoter reverse transcriptase TERT gene increase expression...
We have analyzed the presence of immature and mature dendritic cells (DCs) within adenocarcinoma breast using immunohistochemistry. Immature DCs were defined by expression CD1a-, Langerin-, intracellular major histocompatibility complex class II-rich vesicles. Mature CD83 DC-Lamp. Breast carcinoma morphology and/or cytokeratin expression. demonstrate two levels heterogeneity infiltrating tissue: (a) CD1a(+) DCs, mostly Langerhans cell type (Langerin(+)), retained tumor bed in 32/32 samples...
Lymphocyte activation gene-3 (LAG-3) is a cell-surface molecule with diverse biologic effects on T cell function. We recently showed that LAG-3 signaling important in CD4+ regulatory suppression of autoimmune responses. Here, we demonstrate maintains tolerance to self and tumor antigens via direct CD8+ cells using 2 murine systems. Naive express low levels LAG-3, expression increases upon antigen stimulation. Our data show increased protein antigen-specific within antigen-expressing organs...
BACKGROUND: Malignant cells must maintain their telomeres, but genetic mechanisms responsible for telomere maintenance in tumors have only recently been discovered. In particular, mutations of the binding proteins alpha thalassemia/mental retardation syndrome X-linked (ATRX) or death-domain associated protein (DAXX) shown to underlie a mechanism not involving telomerase (alternative lengthening telomeres), and point promoter reverse transcriptase (TERT) gene increase expression occur...
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis include management options localized, regional, metastatic disease. Recommendations disease monitoring treatment of recurrent are also included. Panel meets annually to reevaluate update their recommendations based on new clinical data input from within Member Institutions external entities. This article summarizes the panel’s discussions 2021 guidelines with regard systemic therapy...
Perivascular epithelioid cell neoplasms (PEComas) include the common renal angiomyolipoma, pulmonary clear sugar tumor, lymphangioleiomyomatosis, and less of soft tissue, gynecologic, gastrointestinal tracts. Recently, aberrant immunoreactivity for TFE3 protein (a sensitive specific marker harboring gene fusions) has been reported in as many 100% PEComas; however, status these not systematically investigated. We used a fluorescence situ hybridization (FISH) break-apart assay to evaluate...
Michael C. Haffner 1 , Alcides Chaux 2 Alan K. Meeker 1,2,3 David M. Esopi Jonathan Gerber 4 Laxmi G. Pellakuru Antoun Toubaji Pedram Argani 1,2 Christine Iacobuzio-Donahue William Nelson George J. Netto Angelo De Marzo Srinivasan Yegnasubramanian Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA Department of Pathology, 3 Brady Urological Institute, Medicine, Division Hematology, School Received: September 1, 2011; Accepted: Published: 2,...
Abstract Purpose: Analytically validated assays to interrogate biomarker status in clinical samples are crucial for personalized medicine. PTEN is a tumor suppressor commonly inactivated prostate cancer that has been mechanistically linked disease aggressiveness. Though deletion of PTEN, as detected by cumbersome FISH spot counting assays, associated with poor prognosis, few studies have immunohistochemistry (IHC) determine whether loss protein unfavorable disease. Experimental Design: IHC...
Abstract Purpose: Small cell neuroendocrine carcinoma of the prostate is likely to become increasingly common with recent advances in pharmacologic androgen suppression. Thus, developing molecular markers small differentiation cancer will be important guide diagnosis and therapy this aggressive tumor. Experimental Design: We examined status RB1, TP53, PTEN prostatic acinar carcinomas via immunohistochemistry (IHC), copy-number alteration analysis, sequencing formalin-fixed paraffin-embedded...
Cancers comprise a heterogeneous group of human diseases. Unifying characteristics include unchecked abilities tumor cells to proliferate and spread anatomically, the presence clonal advantageous genetic changes. However, universal highly specific markers are unknown. Herein, we report widespread long interspersed element-1 (LINE-1) repeat expression in cancers. We show that nearly half all cancers immunoreactive for LINE-1-encoded protein. LINE-1 protein is common feature many types...
The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions regarding the workup of patients with prostate cancer, risk stratification and management localized disease, post-treatment monitoring, treatment recurrence advanced disease. sections included in this article focus metastatic castration-sensitive nonmetastatic castration-resistant cancer (CRPC), CRPC (mCRPC). Androgen deprivation therapy (ADT) intensification is strongly recommended cancer. For CRPC, ADT...
Abstract Activating mutations occur in the promoter of telomerase reverse transcriptase (TERT) gene 66% muscle-invasive urothelial carcinomas. To explore their role bladder cancer development and to assess utility as urine markers for early detection, we sequenced TERT 76 well-characterized papillary flat noninvasive carcinomas, including 28 pTa low-grade transitional cell carcinomas (TCC), 31 high-grade TCCs, 17 pTis carcinoma situ lesions. We also evaluated sequence a separate series 14...
What's known on the subject? and What does study add? Steroid hormone receptor signals have been implicated in bladder tumourigenesis tumour progression. The expression of androgen and/or oestrogen receptors has assessed cancer, leading to conflicting data levels their relationship histopathological characteristics tumours. We simultaneously analyze three non‐neoplastic tissues as well primary metastatic specimens. Our demonstrate that status correlates with grades/stages patients’ outcomes....
Xp11 translocation cancers include renal cell carcinoma (RCC), perivascular epithelioid tumor (PEComa), and melanotic cancer. In cancers, oncogenic activation of TFE3 is driven by the fusion with a number different gene partners; however, impact individual variant on specific clinicopathologic features has not been well defined. this study, we analyze 60 fluorescence in situ hybridization using custom bacterial artificial chromosome probes to establish their partner. 5 cases RNA sequencing...
We previously demonstrated the ability to detect metastatic prostate cancer using <i>N</i>-[<i>N</i>-[(<i>S</i>)-1,3-dicarboxypropyl]carbamoyl]-4-<sup>18</sup>F-fluorobenzyl-l-cysteine (<sup>18</sup>F-DCFBC), a low-molecular-weight radiotracer that targets prostate-specific membrane antigen (PSMA). PSMA has been shown be associated with higher Gleason grade and more aggressive disease. An imaging biomarker able clinically significant high-grade primary reliably would address an unmet...